ResMed Price Target Raised 1.5% to A$47.50/Share by Macquarie

What happened

Macquarie raised its price target for ResMed by 1.5% to A$47.50 per share. The supplied report provides no explanation for the increase and gives no other details about ResMed’s business or Macquarie’s assumptions.

Confirmed

Global impact / market context

A price target is an analyst’s estimate of a share’s potential value, not a company commitment or a guaranteed market price. A higher target can shape investor expectations about ResMed shares, but the brief report does not explain what earnings, sales, or costs support Macquarie’s change.

Analyst inference

The only supplied context is Macquarie’s target revision; it does not report ResMed’s share-price move, financial results, or any change to its outlook. So the revision alone does not establish whether the target is above or below the current share price or whether investors agree.

Analyst inference

What to watch

1. Look for further details from Macquarie about the assumptions behind its revised target, such as expected sales or costs; none are given in the supplied report. Analyst inference
2. Check ResMed’s next reported results and outlook for evidence of changes in revenue or expenses that could support or challenge the target revision. Analyst inference
3. Compare the A$47.50 target with ResMed’s share price when available; the supplied report does not state the current price or any market reaction. Analyst inference

Evidence

• Original source link unavailable